Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
8
×
life sciences
national blog main
sanofi
8
×
boston top stories
clinical trials
national top stories
san francisco blog main
san francisco top stories
ipo
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
fda
investing
roche
startups
abbvie
cancer drugs
cancer immunotherapy
johnson & johnson
What
ipo
medicines
roundup
bio
cancer
drug
american
annual
companies
latest
pharmaceutical
proteins
reach
research
revolution
society
today
acquisitions
ahead
alzheimer’s
ambien
announced
asco
ash
attendees
attention
biotech
black
blood
borne
camp’s
cancers
cancer’s
cash
ceo
chicago
city
clinical
collabs
combinations
Language
unset
Current search:
sanofi
×
cancer
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More